Skin-cup, cream 0.2% 15 g

Pharmgroup: < br>

Preparation with antiproliferative, antibacterial and antifungal action for external use

Pharmaceutical action: < br>

Zinc pyrithione activated has anti-inflammatory, antibacterial and antifungal activity. Antifungal activity is especially expressed against Pityrosporum ovale and Pityrosporum orbiculare causing inflammation and excessive peeling in skin diseases. Antibacterial activity is shown against a number of pathogenic microorganisms Streptococcus spp., Staphylococcus spp., Escherichia coli, Pseudomonas aeruginosa, Proteus spp.

Zinc pyrithione reduces intracellular ATP level, promotes depolarization of cell membranes, causing death of fungi and bacteria. The mechanism of anti-inflammatory action is not studied.

Pharmacokinetics:

When applied externally, zinc pyrithione is deposited in the epidermis and superficial layers of the dermis. Systemic absorption occurs slowly. It is detected in the blood in trace amounts.

Indications

Psoriasis, atopic dermatitis, eczema, neurodermatitis, dry skin, seborrheic dermatitis in adults and children from 1 year.

Pharmacological effect

Pharmaceutical group:

A drug with antiproliferative, antibacterial and antifungal effects for external use

Pharmaceutical action:

Activated zinc pyrithione has anti-inflammatory, antibacterial and antifungal activity. Antifungal activity is especially pronounced against Pityrosporum ovale and Pityrosporum orbiculare, which cause inflammation and excessive peeling in skin diseases. Antibacterial activity is manifested against a number of pathogenic microorganisms Streptococcus spp., Staphylococcus spp., Escherichia coli, Pseudomonas aeruginosa, Proteus spp.

Zinc pyrithione reduces the intracellular level of ATP, promotes depolarization of cell membranes, causing the death of fungi and bacteria. The mechanism of anti-inflammatory action has not been studied.

Pharmacokinetics:

When applied externally, zinc pyrithione is deposited in the epidermis and superficial layers of the dermis. Systemic absorption occurs slowly. Found in the blood in trace amounts.

Special instructions

If the drug gets into your eyes, rinse them with plenty of cold water.

Active ingredient

Pyrithione zinc

Composition

100 g of the drug contains:
Active ingredient: pyrithione zinc activated 200 mg.
Excipients: glycerol mono- and distearate (Tegin M), capryl caprylate (Tegosoft EE), methyldextrose and macrogol-20 ether (Tegosoft E20), isopropyl palmitate (Tegosoft R), methyldextrose polyglyceryl distearate (Tego Care 450), butylated hydroxytoluene, glycerol, propyl parahydroxybenzoate (Nipagin), sucrose and coconut oil fatty acid ester (Tegosoft LSE 65K), stearyl alcohol (Tego Alkanol 18), ethanol, flavoring (citronellol, phenylethanol, geraniol, terpineol, cinnamic alcohol), cyclomethicone (Abil K 4), water.

Pregnancy

During pregnancy and lactation, the drug should be prescribed only in cases where the expected benefit of therapy for the mother outweighs the potential risk for the fetus or infant.

There have been no reports of any adverse effects from the use of zinc pyrithione preparations by pregnant women or women during breastfeeding.

Contraindications

Hypersensitivity to the components of the drug.

Side Effects

Allergic reactions.
In the first days of treatment, a short-term burning sensation is possible at the site of application of the drug, which, as a rule, does not require discontinuation of the drug.

Storage conditions

At temperatures from +4 to +20 °C, out of the reach of children.

Shelf life

3 years

Manufacturer

B.Brown Medical S.A., Spain